联邦制药宣布,其生产的罗红霉素胶囊已顺利通过中国国家药品监督管理局(NMPA)组织的一致性评价。这一重要进展标志着该药品在质量与疗效方面达到国家规定标准,为企业后续市场拓展奠定坚实基础。
联邦制药宣布,其生产的罗红霉素胶囊已顺利通过中国国家药品监督管理局(NMPA)组织的一致性评价。这一重要进展标志着该药品在质量与疗效方面达到国家规定标准,为企业后续市场拓展奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.